Life-threatening intoxication with methylene bis(thiocyanate): clinical picture and pitfalls. A case report by Braun, Claude et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Emergency Medicine
Open Access Case report
Life-threatening intoxication with methylene bis(thiocyanate): 
clinical picture and pitfalls. A case report
Claude Braun*1,3, Rainer Birck1, Manfred V Singer2, Peter Schnuelle1, 
Fokko J van der Woude1 and Matthias Löhr2
Address: 1Department of Medicine V (Nephrology/Endocrinology/Rheumatology), University Medical Center Mannheim, University of 
Heidelberg, D-68135 Mannheim, Germany, 2Department of Medicine II (Gastroenterology/Hepatology/Infectious Diseases), University Medical 
Center Mannheim, University of Heidelberg, D-68135 Mannheim, Germany and 3Départment de Médecine Interne et Néphrologie, Centre 
Hospitalier Kirchberg, L-2540 Luxembourg
Email: Claude Braun* - cbraun@rumms.uni-mannheim.de; Rainer Birck - rainer.birck@med5.ma.uni-heidelberg.de; 
Manfred V Singer - manfred.v.singer@med.ma.uni-heidelberg.de; Peter Schnuelle - peter.schnuelle@med5.ma.uni-heidelberg.de; Fokko J van 
der Woude - fokko.van-der-woude@med5ma.uni-heidelberg.de; Matthias Löhr - matthias.loehr@med.ma.uni-heidelberg.de
* Corresponding author    
Abstract
Background: Methylene bis(thiocyanate) (MBT) is a microbiocidal agent mainly used in industrial
water cooling systems and paper mills as an inhibitor of algae, fungi, and bacteria.
Case presentation: We describe the first case of severe intoxication following inhalation of
powder in an industrial worker. Profound cyanosis and respiratory failure caused by severe
methemoglobinemia developed within several minutes. Despite immediate admission to the
intensive care unit, where mechanical ventilation and hemodialysis for toxin elimination were
initiated, multi-organ failure involving liver, kidneys, and lungs developed. While liver failure was
leading, the patient was successfully treated with the MARS (molecular adsorbent recirculating
system) procedure.
Conclusion: Intoxication with MBT is a potentially life-threatening intoxication causing severe
methemoglobinemia and multi-organ failure. Extracorporeal liver albumin dialysis (MARS) appears
to be an effective treatment to allow recovery of hepatic function.
Background
Extracorporal albumin dialysis using the Molecular
Adsorbent Recirculating System (MARS®) is now used in
many hospitals to support excretory hepatic function.
Main indications are acute-on-chronic liver failure, acute
liver failure, primary graft dysfunction after liver trans-
plantation, and liver failure post liver surgery [1-3]. The
MARS procedure allows removal of the protein-bound
toxins, such as bilirubin, phenols, or "false" neurotrans-
mitters, improvement of hepatorenal syndrome, and the
creation of a "bridge" for patients awaiting urgent liver
transplantation. Theoretically this treatment is suggestive
to be of value in intoxications in which the liver represents
the main target organ, either by eliminating protein-
bound substances not removed by other extracorporeal
procedures, or by supporting excretory hepatic function,
thereby allowing spontaneous recovery of the failing liver
or transplantation of a suitable graft. Here we report an
unusual case of acute liver failure secondary to intoxica-
tion with MBT successfully treated with MARS.
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Case presentation
A 39 year old industrial worker with no former medical
history suddenly complained of nausea, dizziness, respi-
ratory tract irritation, and dyspnea during sweeping sev-
eral kilograms of a powder that had escaped from a barrel
containing methylene bis(thiocyanate) (MBT). The
worker was not wearing any personal protective equip-
ment. Profound cyanosis developed, and the patient was
admitted in our hospital, where mechanical ventilation
with 100% oxygen was initiated. 4-dimethylaminophenol
(4-DMAP; 250 mg) followed by sodium-thiosulfate
(6000 mg) were immediately administered intravenously
for treatment of assumed cyanide intoxication. Arterial
blood gas examination by co-oxymeter performed a few
minutes later revealed the following arterial-blood gas
values: pH 7.39, partial pressure of carbon dioxide 37
mmHg, partial pressure of oxygen 381 mmHg, oxygen sat-
uration 63%, methemoglobin level of 51%, oxyhemo-
globin level of 48%, carboxyhemoglobin level 0.4%. The
i.v. administration of tolonium chloride (toluidine blue,
300 mg, repeated once within 30 minutes) lowered the
methemoglobin level to 12% within one hour. The
patient was transferred to the medical ICU. In the mean-
time information on MBT toxicity was requested from sev-
eral German Intoxication centers. Given the lack of a
specific antidot, the experts at these centers recommended
treatment with hemodialysis for toxin elimination in
addition to general supportive care and monitoring of
renal, hepatic and pulmonary function. Only very limited
data, however, provided the rationale for these measures,
and most information was obtained from anecdotal
reports of intoxication with methyl-isocyanate, a chemical
analogue of MBT (the accidental release of a methyl-isocy-
anate cloud (composed of phosgene and isocyanate) was
implicated in the Bhopal, India, disaster in 1984) [4,5].
Laboratory and pulsoxymetric evaluation were markedly
impeded by the bluish discoloration of skin and serum
samples after toluidine blue administration. Daily hemo-
dialysis treatment was started. On the second day a slight
increase in renal retention parameters and transaminases
was observed, together with massive hemolysis (hemo-
globin decrease from 14.5 to 8.8 g/dl, LDH > 6000 U/l,
haptoglobin < 0.3 g/l) and an increase of methemoglobin
from 13 to 34%, all attributed to MBT toxicity. A total of
seven units of packed red cells were administered. In the
following days, anuric acute renal failure and adult respi-
ratory distress syndrome developed, making the initiation
of continuous veno-venous hemofiltration and adoption
of a more aggressive ventilation strategy necessary. Hemo-
lysis recovered spontaneously, but the further course of
intensive care treatment was complicated by progressive
hepatic failure with prominent hyperbilirubinemia and
increasing liver function impairment (TBIL 16.5 mg/dl,
DBIL 13.0 mg/dl, ALAT 50 U/l, ASAT 49 U/l, CHE 2820
U/l, prothrombine time 51%, INR 1.83, aPTT 34.9 sec,
fibrinogen 2.03 g/l, AT III 81%). Extrahepatic cholestasis
was excluded by ultrasonographic examination, and no
clinical or laboratory signs of sepsis could be found. Three
sessions of treatment with MARS (MARS monitor, Terak-
lin AG, Rostock, Germany) were performed on days 17,
18, and 22 after hospital admission in combination with
ordinary hemodialysis (F8 HPS hemofilter, dialysate flow
800 ml/min, Fresenius 4008H, Fresenius Medical Care
AG, Bad Homburg, Germany) using albumin dialysate
and blood flow rates of approximately 150–180 ml/min
for 7 to 8 hours each session. Anticoagulation with unfrac-
tionated heparin was monitored by activated clotting time
(target range: 160–180 seconds). After the first procedure
the bilirubin level decreased by 46%. The final bilirubin
level after the third MARS session was 6.0 mg/dl. Liver
function and the general condition then recovered, and
the patient could be extubated 2 days after the third liver
dialysis treatment. Due to persisting anuric renal failure, a
permanent dialysis catheter for chronic hemodialysis
treatment was implanted. The patient was discharged on
a peripheral ward on day 36 after hospital admission.
Renal function slowly recovered over the next days, and
the patient could finally be withdrawn from hemodialysis
program on day 44 of his hospital stay. The further course
was complicated by a severe peripheral neuropathy that
was characterised electrophysiologically by a predomi-
nantly axonal damage pattern. Differential diagnosis
included critical-illness neuropathy and MBT-mediated
neurotoxicity. The patient was transferred to a rehabilita-
tion centre. Final blood chemistry at our hospital
included following results: creatinine 1.42 mg/dl, urea 62
mg/dl, TBIL 2.7 mg/dl, ALAT 125 U/l, ASAT 59 U/l, CHE
3667 U/l, hemoglobine 9.1 g/dl, LDH 175 U/l, and pro-
thrombine time 99 % (Table 1).
Conclusion
Methylene bis(thiocyanate) (MBT) is used as a biocide in
a number of industrial and residential applications [6,7].
A chemical overview is presented in Table 2. MBT was first
registered in the US in 1949 as an active ingredient. Cur-
rently 49 active products are registered in the Office of
Pesticide Programs Database [7,8], such as adhesives,
coatings, fuels and various other speciality industrial
products primarily used as a preservative and as an inhib-
itor of algae, fungi, and bacteria in reverse osmosis and
cooling water systems, leather processing and paper mills.
It is also used as a protection treatment of wood and wood
surfaces and is not limited in its efficacy by the presence of
organic matter and oils. MBT consists of a methane group
containing two thiocyanate groups, presenting as a yellow
granular solid with sulphur like smell. Toxicological data-
base is far from being complete for all current use patterns
[6,7,9]. A hazard has been identified for inhalation expo-
sure, since harmful concentrations of airborne particles
can be reached quickly. Furthermore MBT can causeBMC Emergency Medicine 2006, 6:5 http://www.biomedcentral.com/1471-227X/6/5
Page 3 of 4
(page number not for citation purposes)
severe skin irritation. Persons handling this product are
therefore advised to wear goggles or face shields and rub-
ber gloves. Dispersion of MBT containing dust must be
avoided.
There is still a data gap for metabolism primarily due to
inadequate metabolite idenfication [7]. In rats, up to 99%
of [14C]MBT were excreted over a 4-day period. Urine was
the primary route of excretion (55–70%), followed by
fecal elimination (15–30%) and expired CO2 (10–15%).
It is tempting to speculate that fecal elimination is most
likely achieved via biliary excretion of MBT and/or toxic
metabolites. This would help to explain the cholestatic
pattern of acute liver failure observed in our patient. Radi-
olabeled compounds found in fecal extracts from rats
treated with high, but not in those with low, doses were
identified as [14C]MBT (Brown L et al., Inveresk Research
International, unpublished data). However the data pro-
vided on the identification of the metabolites in the urine,
feces, expired air, and tissue is incomplete. Total radioac-
tivity in the blood, blood cyanide and plasma thiocyanate
exhibited biphasic elimination from the blood. The termi-
nal elimination phase started 1 hour after dosing and had
a half-life of 7 hours. The following mechanisms of
metabolism were proposed: One is the reaction of alkyl-
mono-thiocyanates with a soluble liver enzyme fraction
containing glutathione S-transferase and glutathione. A
second reaction involves P-450 isoenzymes. The addi-
tional thiocyanate group may make the methylene carbon
suitable for oxygen insertion producing the correspond-
ing aldehyde with the release of thiocyanate. Further oxi-
dation of the aldehyde to the corresponding acid followed
by decarboxylation would yield CO2. Toxicity of MBT
would therefore be due to 1) cyanide release, 2) glutath-
ione depletion, and 3) toxic metabolites other than cya-
nides and thiocarbamates. Hydrolysis studies indicate
that MBT degrades to thiocyanate ion, formic acid, and
mercapto-(methylenethiocyanate) depending on the pH
of the medium. So far, however, it is not clear whether
degradation to cyanide occurs in the working environ-
ment. In the present case the latter possibility could be
excluded by biochemical analysis of a serum specimen
obtained at the time of hospital admission, in which no
cyanide could be detected. In addition patients with acute
cyanide intoxication typically develop severe lactic acido-
sis, which was not observed in the present case.
Toxicity studies in rats and mice reported signs and symp-
toms comparable to those of acute cyanide intoxication
and included dyspnea, tremors, and ataxia after MBT
doses up to 160 mg/kg body weight [10]. In animals sur-
viving for at least 24 hours, the stomach was identified as
the target organ, demonstrating necrotic inflammatory
lesions of the mucosal surface. After 13 week administra-
tion rats treated with MBT (up to 16 mg/kg) developed
mild anemia, and sperm motility was decreased in male
rats. No mutagenic properties were observed in S. typh-
imurium, with or without S9 activation.
Two occupational incidents were reported to the Office of
Pesticide Programs Incident Data System [7]. The first
involved a man who was exposed to MBT while dipping
Table 1: Selected Blood Chemistry Before and After Treatment with MARS Albumin Liver Dialysis
At admission 
(day 0)
Before first MARS 
session (day 16)
After first MARS 
session (day 17)




TBIL (mg/dl) 0.6 16.5 8.9 5.9 2.7
DBIL (mg/dl) n.a. 13.0 n.a. 3.1 n.a.
ALAT (U/l) 23 50 n.a. 79 125
ASAT (U/l) 17 49 n.a. 34 59
Prothrombine time (%); [INR] 90 [0.98] 68 [1.51]* 64 [1.56] 95 [0.97] 99 [0.96]
CHE (U/l) 5577 2820 2237 2766 3667
Creatinine (mg/dl) 1.04 5.70 2.78 3.48 1.42
* 4 units of fresh frozen plasma had previously been administered.
TBIL: total bilirubine; DBIL: direct bilirubine; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; INR: international normalized 
ratio; CHE: cholinesterase; n.a.: not available
Table 2: Chemical Overview of Methylene (Bis)Thiocyanate
Common name: Methylene bis(thiocyanate)
Methylene dithiocyanate
Thiocyanic acid, methylene ester
Chemical name: Methylene bis(thiocyanate)
CAS Registry Number: 6317-18-6








Basic manufacturers (USA): Akzo Chemicals, Inc.
Albright and Wilson, Ltd.
Buckman Laboratories International, 
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lumber. He developed swollen eyes, a rash on his cheeks
and insomnia. The man was diagnosed lupus erythema-
todes during follow-up; a causal relationship to the pesti-
cide was considered improbable. In the second incident, a
man was exposed to a multiple active ingredient formula-
tion containing 10% MBT through a leaking line. He
developed a rash on his arm, shortness of breath and a
cough, but fully recovered within 24 hours. Clearly the
patient reported here had a much more severe course after
inhalational exposure to MBT, exhibiting a biphasic pat-
tern with methemoglobinemia and hemolytic anemia
immediately after hospital admission and life-threatening
multi-organ failure involving liver, kidneys and lungs in
the following days. Although we cannot formally prove a
causal relationship on the basis of the present case
description, inhalational MBT uptake most likely
accounts for the described complications. Glucose-6-
phosphate-dehydrogenase deficiency, known to exagger-
ate methylene blue toxicity and cause acute hemolysis,
was excluded later during the hospital stay. The molecular
basis of MBT toxicity remains unclear, although it is most
probably not related to the production of cyanide, but
rather to methemoglobinemia.
This case is, to our best knowledge, the first report of a
multi-organ failure secondary to inhalation of methylene-
bis-thiocyanate and one of the first reports of the success-
ful use of MARS albumin dialysis in hepatic failure due to
intoxication [11-13]. This case underlines the diagnostic
and therapeutic dilemma of emergency physicians faced
with unusual intoxications. A direct effect of MARS on
MBT metabolism or on toxin elimination is very unlikely,
as our patient has been treated with MARS only after more
than 14 days of extracorporeal renal replacement therapy.
MARS albumin dialysis therefore appears to be an effec-
tive treatment to allow recovery of liver function after
severe intoxication or, in the case of more fulminant liver
disease, bridge patients awaiting urgent liver transplanta-
tion.
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